Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.
Pharmacokinetic parameters of zidovudine (ZDV) were not altered in 16 patients receiving concomitant therapy with ZDV and trimethoprim-sulfamethoxazole by oral administration. ZDV areas under the concentration-time curves were (means +/- standard deviations) 1.80 +/- 0.70 and 1.69 +/- 0.64 micrograms.h/ml in the absence and presence of trimethoprim-sulfamethoxazole, respectively. ZDV clearances were 1.57 +/- 0.61 and 1.74 +/- 0.66 liters/h/kg, respectively.
Cañas
E
E
Infectious Diseases Unit, Hospital Universitario Virgen del Rocio, Seville, Spain.
Pachon
J
J
Garcia-Pesquera
F
F
Castillo
J R
JR
Viciana
P
P
Cisneros
J M
JM
Jimenez-Mejias
M E
ME
D000328:Adult; D000935:Antifungal Agents / Q000493:pharmacokinetics*; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000378:metabolism; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology*; D015215:Zidovudine / Q000493:pharmacokinetics*
D000935:Antifungal Agents; D000998:Antiviral Agents; D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination